Reaction
Tumour Flare reporting signals
As of the last recalculation, Tumour Flare appears in 674 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is OBINUTUZUMAB (PRR 75.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Obinutuzumab | 38 | 75.5 | 75.7 |
| Polatuzumab Vedotin | 12 | 38.6 | 38.7 |
| Brentuximab Vedotin | 11 | 33.7 | 33.7 |
| Goserelin | 13 | 30.5 | 30.5 |
| Drs. Clotrimazole | 11 | 29.9 | 29.9 |
| Family Wellness Clotrimazole | 11 | 29.9 | 29.9 |
| Clotrimazole Topical | 11 | 29.8 | 29.9 |
| Clotrimazole | 11 | 28.1 | 28.1 |
| Allopurinol | 114 | 26.9 | 26.9 |
| Bendamustine Hcl | 13 | 26.4 | 26.4 |
| Lenalidomide | 237 | 26.2 | 26.2 |
| Bendamustine Hydrochloride | 8 | 20.9 | 20.9 |
| Fludarabine Phosphate | 25 | 20.4 | 20.4 |
| Piperacillin Sodium,Tazobactam Sodium | 16 | 19.1 | 19.1 |
| Abemaciclib | 11 | 17.3 | 17.3 |
| Pemetrexed | 8 | 11.6 | 11.7 |
| Axicabtagene Ciloleucel | 3 | 9.4 | 9.4 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 4 | 9.4 | 9.4 |